ObGyn
Partner With Us
Advertisement
Conexiant chevron_right ObGyn chevron_right FDA Approves Enhertu for Metastatic HRPositive HER2 Low or Ultralow Breast Cancer
From the Journals Conference News FDA & Government News 2024 ASCO Annual Meeting

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

Conexiant
article Full Article subject Summary summarize Notecard
Enhertu, an FDA-approved HER2-directed therapy, has shown significant progress in treating unresectable or metastatic hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer. Trastuzumab deruxtecan has extended progression-free survival, redefining treatment paradigms and introducing a new standard of care for patients with limited therapeutic options after endocrine therapy.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.